Takeda Pharmaceutical
Market Cap
JP¥5.9t
Last Updated
2021/03/08 08:13 UTC
Data Sources
Company Financials +
Executive Summary
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. More Details
Rewards
Risk Analysis
Snowflake Analysis
Solid track record second-rate dividend payer.
Similar Companies
Share Price & News
How has Takeda Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4502 is less volatile than 75% of JP stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4502's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
8.1%
4502
0.4%
JP Pharmaceuticals
-0.9%
JP Market
1 Year Return
6.1%
4502
18.7%
JP Pharmaceuticals
36.1%
JP Market
Return vs Industry: 4502 underperformed the JP Pharmaceuticals industry which returned 12.9% over the past year.
Return vs Market: 4502 underperformed the JP Market which returned 28.5% over the past year.
Shareholder returns
| 4502 | Industry | Market | |
|---|---|---|---|
| 7 Day | 8.1% | 0.4% | -0.9% |
| 30 Day | 6.3% | -5.2% | -0.4% |
| 90 Day | 1.2% | -2.3% | 7.0% |
| 1 Year | 11.5%6.1% | 21.2%18.7% | 39.5%36.1% |
| 3 Year | -22.0%-31.3% | 25.2%16.6% | 16.6%8.6% |
| 5 Year | -13.3%-28.6% | 46.5%30.3% | 53.8%36.8% |
Long-Term Price Volatility Vs. Market
How volatile is Takeda Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Takeda Pharmaceutical undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 4502 (¥3905) is trading below our estimate of fair value (¥8240.26)
Significantly Below Fair Value: 4502 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 4502 is poor value based on its PE Ratio (33.7x) compared to the JP Pharmaceuticals industry average (22.2x).
PE vs Market: 4502 is poor value based on its PE Ratio (33.7x) compared to the JP market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: 4502 is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: 4502's PB Ratio (1.3x) is in line with the JP Pharmaceuticals industry average.
Next Steps
Future Growth
How is Takeda Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
19.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4502's forecast earnings growth (19.8% per year) is above the savings rate (0%).
Earnings vs Market: 4502's earnings (19.8% per year) are forecast to grow faster than the JP market (17.4% per year).
High Growth Earnings: 4502's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4502's revenue (0.8% per year) is forecast to grow slower than the JP market (5.7% per year).
High Growth Revenue: 4502's revenue (0.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4502's Return on Equity is forecast to be low in 3 years time (9.9%).
Next Steps
Past Performance
How has Takeda Pharmaceutical performed over the past 5 years?
0.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4502 has high quality earnings.
Growing Profit Margin: 4502's current net profit margins (5.6%) are higher than last year (0.4%).
Past Earnings Growth Analysis
Earnings Trend: 4502 has become profitable over the past 5 years, growing earnings by 0.6% per year.
Accelerating Growth: 4502's earnings growth over the past year (1226.7%) exceeds its 5-year average (0.6% per year).
Earnings vs Industry: 4502 earnings growth over the past year (1226.7%) exceeded the Pharmaceuticals industry 10.9%.
Return on Equity
High ROE: 4502's Return on Equity (3.9%) is considered low.
Next Steps
Financial Health
How is Takeda Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 4502's short term assets (¥2,616.6B) exceed its short term liabilities (¥1,805.0B).
Long Term Liabilities: 4502's short term assets (¥2,616.6B) do not cover its long term liabilities (¥5,841.8B).
Debt to Equity History and Analysis
Debt Level: 4502's debt to equity ratio (101.5%) is considered high.
Reducing Debt: 4502's debt to equity ratio has increased from 31.8% to 101.5% over the past 5 years.
Debt Coverage: 4502's debt is not well covered by operating cash flow (16.9%).
Interest Coverage: 4502's interest payments on its debt are not well covered by EBIT (1.8x coverage).
Balance Sheet
Next Steps
Dividend
What is Takeda Pharmaceutical current dividend yield, its reliability and sustainability?
4.61%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4502's dividend (4.61%) is higher than the bottom 25% of dividend payers in the JP market (1.25%).
High Dividend: 4502's dividend (4.61%) is in the top 25% of dividend payers in the JP market (2.88%)
Stability and Growth of Payments
Stable Dividend: 4502's dividends per share have been stable in the past 10 years.
Growing Dividend: 4502's dividend payments have not increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (155.5%), 4502's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.4yrs
Average management tenure
CEO
Christophe Weber (54 yo)
5.92yrs
Tenure
JP¥2,073,000,000
Compensation
Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...
CEO Compensation Analysis
Compensation vs Market: Christophe's total compensation ($USD19.15M) is above average for companies of similar size in the JP market ($USD1.89M).
Compensation vs Earnings: Christophe's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.92yrs | JP¥2.07b | 0.000020% ¥ 1.2m | |
| CFO & Director | 1.75yrs | JP¥664.00m | 0% ¥ 0 | |
| President of Japan Pharma Business Unit & Director | 8.75yrs | JP¥297.00m | 0% ¥ 0 | |
| President of Research & Development and Director | 5.75yrs | JP¥1.05b | no data | |
| Chair of Management Board | no data | no data | no data | |
| Member of Management Board | no data | no data | no data | |
| Member of Management Board and Head of R&D Global Science & Biomedical Policy | no data | no data | no data | |
| Senior Vice President of Corporate Finance & Controlling Department | 8yrs | no data | no data | |
| Global Head of Investor Relations & Global Finance | 0.50yr | no data | no data | |
| Global General Counsel | 6.42yrs | no data | no data | |
| Chief Ethics & Compliance Officer | 6.42yrs | no data | no data | |
| Vice President of Global Licensing & Business Development Department | 9.17yrs | no data | no data |
6.4yrs
Average Tenure
55yo
Average Age
Experienced Management: 4502's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.92yrs | JP¥2.07b | 0.000020% ¥ 1.2m | |
| CFO & Director | 1.75yrs | JP¥664.00m | 0% ¥ 0 | |
| President of Japan Pharma Business Unit & Director | 8.75yrs | JP¥297.00m | 0% ¥ 0 | |
| President of Research & Development and Director | 5.75yrs | JP¥1.05b | no data | |
| Member of Takeda Global Advisory Board | no data | no data | no data | |
| Member of Takeda Global Advisory Board | no data | no data | no data | |
| Independent External Director | 4.75yrs | JP¥43.00m | no data | |
| Member of Takeda Global Advisory Board | 10.42yrs | no data | no data | |
| Independent Chairman of the Board | 3.75yrs | JP¥44.00m | no data | |
| Director | 4.75yrs | JP¥50.00m | 0% ¥ 0 | |
| Independent External Director | 1.75yrs | JP¥40.00m | 0% ¥ 0 | |
| Independent External Director | 4.75yrs | JP¥42.00m | 0% ¥ 0 |
4.8yrs
Average Tenure
63.5yo
Average Age
Experienced Board: 4502's board of directors are considered experienced (4.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Takeda Pharmaceutical Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Takeda Pharmaceutical Company Limited
- Ticker: 4502
- Exchange: TSE
- Founded: 1781
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥5.875t
- Shares outstanding: 1.56b
- Website: https://www.takeda.com
Number of Employees
Location
- Takeda Pharmaceutical Company Limited
- 1-1, Nihonbashi-Honcho 2-chome
- Chuo-ku
- Tokyo
- 103-8668
- Japan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TKPH.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Jan 1992 |
| 4502 | TSE (The Tokyo Stock Exchange) | Yes | Common Stock | JP | JPY | Jan 1992 |
| 0RN3 | LSE (London Stock Exchange) | Yes | Common Stock | GB | EUR | Jan 1992 |
| TKD | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1992 |
| TAK | NYSE (New York Stock Exchange) | SPON ADS EACH REP 0.5 ORD SHS | US | USD | May 2010 | |
| TAK N | BMV (Bolsa Mexicana de Valores) | SPON ADS EACH REP 0.5 ORD SHS | MX | MXN | May 2010 | |
| TKDA | BST (Boerse-Stuttgart) | SPON ADS EACH REP 0.5 ORD SHS | DE | EUR | May 2010 | |
| TKDA | DB (Deutsche Boerse AG) | SPON ADS EACH REP 0.5 ORD SHS | DE | EUR | May 2010 | |
| TAKP34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH REP 1 ADR | BR | BRL | Oct 2019 |
Biography
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other h...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/08 08:13 |
| End of Day Share Price | 2021/03/08 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.